Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy



Status:Completed
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:6/17/2018
Start Date:September 23, 2011
End Date:April 3, 2017

Use our guide to learn which trials are right for you!

Phase II Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy

The investigators propose to evaluate eribulin as adjuvant therapy in breast cancer patients
who have residual invasive disease in breast or lymph node tissue following standard
neoadjuvant chemotherapy and surgery regimen. Three cohorts of patients will be evaluated
separately based on tumor type: triple-negative, hormone-receptor-positive/HER2-negative, and
HER2-positive breast cancers.

This is a non-randomized, open-label trial to evaluate 6 cycles of eribulin in female
patients with invasive breast cancer who do not achieve pathologic complete response (pCR)
after treatment with a standard neoadjuvant chemotherapy and surgery regimen. Patients will
be randomized into three cohorts according to tumor-type: triple-negative (Cohort A),
hormone-receptor-positive/HER2-negative (Cohort B), and HER2-positive (Cohort C) tumors.
Patients will receive eribulin for 6 cycles (1 cycle = 21 days). Patients with HER2-positive
tumors will also receive trastuzumab. Patients in all cohorts will be allowed to receive
locoregional radiotherapy and/or adjuvant hormonal therapy per institutional guidelines.

Inclusion Criteria:

1. Female patients >=18 years-of-age.

2. Histologically confirmed breast cancer prior to surgery with the following staging
criteria: T1-T3, T4a, T4b, N0-N2, N3a and M0 (T1N0M0 patients are excluded).
Inflammatory disease is excluded.

3. Previous treatment with a minimum of 4 cycles of neoadjuvant anthracycline and/or
taxane containing chemotherapy (+trastuzumab in HER2-positive patients).

4. Patients must be ≥ 21 days and ≤ 84 days from breast surgery and fully recovered.
Patients may have had mastectomy or breast conservation surgery with axillary node
dissection.

5. Pathologic CR (pCR) not achieved following neoadjuvant treatment (i.e., residual
invasive breast cancer (>5 mm) in the breast or presence of nodal disease at surgery
[ypT0/T1a, N1-N3a, M0 or ypT1b-T4, N0-N3a, M0].

6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.

7. Recovery from any toxic effects of prior therapy to <=Grade 1 per the National Cancer
Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v4.0) except
fatigue or alopecia.

8. Peripheral neuropathy Grade <=2 per NCI CTCAE v4.0 at trial entry.

9. Normal left ventricular ejection fraction (LVEF), within the institutional limits of
normal, as measured by echocardiography (ECHO) or multi-gated (MUGA) scan in patients
to receive trastuzumab with eribulin (HER2-positive).

10. Adequate hematologic, hepatic, and renal function

11. Complete staging work-up to confirm localized disease should include computed
tomography (CT) scans of the chest and abdomen/pelvis (abdomen/pelvis preferred;
abdomen accepted), a CT scan of the head or MRI of the brain (if symptomatic), and
either a positron emission tomography (PET) scan or a bone scan. (Note: a PET/CT is
acceptable for baseline imaging in lieu of CT examinations or bone scan). Negative
scans performed prior to the initiation of neoadjuvant therapy, or at any subsequent
time, are acceptable and do not need to be repeated.

12. Female patients who are not of child-bearing potential and female patients of
child-bearing potential who agree to use adequate contraceptive measures, who are not
breastfeeding, and who have a negative serum pregnancy test performed within 7 days
prior to start of trial treatment.

13. Willingness and ability to comply with trial and follow-up procedures.

14. Ability to understand the investigative nature of this trial and give written informed
consent.

15. Agree to delay in reconstruction in terms of implants placed in setting of expanders
until chemotherapy is completed and the patient has recovered. Expansion of expanders
may continue during trial treatment.

Exclusion Criteria:

1. Presence of other active cancers, or history of treatment for invasive cancer <3 years
prior to trial entry (except thyroid, cervical cancer). Patients with Stage I cancer
who have received definitive local treatment at least 3 years previously, and are
considered unlikely to recur are eligible. All patients with previously treated in
situ carcinoma (i.e., non-invasive) are eligible, as are patients with history of
non-melanoma skin cancer.

2. Radiotherapy prior to the start of study treatment.

3. History or clinical evidence of central nervous system metastases or other metastatic
disease.

4. Non-healed surgical wound.

5. Known or suspected allergy/hypersensitivity to eribulin.

6. Cardiac disease, including: congestive heart failure Class II-IV per New York Heart
Association classification;cardiac ventricular arrhythmias requiring anti-arrhythmic
therapy; unstable angina (anginal symptoms at rest) or new-onset angina (i.e., began
within the last 3 months), or myocardial infarction within the past 6 months.

7. Chronic use of drugs that cause QTc prolongation.Patients must discontinue use of
these drugs 7 days prior to the start of study treatment.

8. Women who are pregnant or lactating. All females of child-bearing potential must have
negative serum pregnancy test within 48 hours prior to trial treatment.

9. Patients with known diagnosis of human immunodeficiency virus (HIV), hepatitis C
virus, or acute or chronic hepatitis B infection.

10. Prolongation of heart rate-corrected QT interval (QTc) >480 msecs (using Bazett's
formula).

11. Minor surgical procedures (with the exception of the placement of port-a-cath or other
central venous access) performed less than 7 days prior to beginning protocol
treatment.

12. History of cerebrovascular accident including transient ischemic attack (TIA), or
untreated deep venous thrombosis (DVT)/ pulmonary embolism (PE) within the past 6
months. Note: Patients with recent DVT/PE receiving treatment with a stable dose of
therapeutic anti-coagulating agents are eligible.

13. Patients may not receive any other investigational or anti-cancer treatments while
participating in this trial.

14. History of any medical or psychiatric condition or laboratory abnormality that in the
opinion of the investigator may increase the risks associated with the trial
participation or investigational product(s) administration or may interfere with the
interpretation of the results.

15. Inability or unwillingness to comply with trial and/or follow-up procedures outlined
in the protocol.
We found this trial at
18
sites
Chattanooga, Tennessee 37404
?
mi
from
Chattanooga, TN
Click here to add this to my saved trials
166 Stoneridge Drive
Columbia, South Carolina 29210
803-461-3000
South Carolina Oncology Associates, PA South Carolina Oncology Associates (SCOA) is the only comprehensive cancer...
?
mi
from
Columbia, SC
Click here to add this to my saved trials
Arlington, Texas 76011
?
mi
from
Arlington, TX
Click here to add this to my saved trials
6410 Rockledge Dr #660
Bethesda, Maryland 20817
(301) 571-0019
Center for Cancer & Blood Disorders Widely recognized for its compassionate, expert care, the Center...
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
5053 Wooster Rd
Cincinnati, Ohio 45226
(513) 751-2273
Oncology Hematology Care Our more than 60 physicians and advanced practice providers throughout neighborhood offices...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Fort Myers, Florida 33916
?
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Fort Myers, Florida 33916
?
mi
from
Fort Myers, FL
Click here to add this to my saved trials
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
743 Spring St NE
Gainesville, Georgia 30501
770-219-9000
Northeast Georgia Medical Center Northeast Georgia Health System (NGHS) is a not-for-profit community health system...
?
mi
from
Gainesville, GA
Click here to add this to my saved trials
?
mi
from
Lakeland, FL
Click here to add this to my saved trials
Morristown, New Jersey 07960
?
mi
from
Morristown, NJ
Click here to add this to my saved trials
Morristown, New Jersey 07960
?
mi
from
Morristown, NJ
Click here to add this to my saved trials
250 25th Ave N, Ste 100
Nashville, Tennessee 37023
615-320-5090
Tennessee Oncology, PLLC Since 1976 Tennessee Oncology has been providing quality cancer care. In 2013,...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Omaha, Nebraska 68114
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Orlando, Florida 32804
?
mi
from
Orlando, FL
Click here to add this to my saved trials
Portland, Maine 04101
?
mi
from
Portland, ME
Click here to add this to my saved trials
Terre Haute, Indiana 47802
?
mi
from
Terre Haute, IN
Click here to add this to my saved trials